NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty contract research organization (“CRO”) based in San Diego, CA and is one of the industry’s most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed is also developing a proprietary product pipeline based on its NexACT(R) drug delivery technology, including a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder and an early stage treatment for psoriasis. For further information, go to www.nexmed.com and www.bio-quant.com.
NEXM is rocking!!
NEXM
NexMed, Inc.
************************************
NEXM is up exactly 100% in the last 20 trading days!!
NEXM has just been granted continued listing on the NASDAQ!!
NEXM has almost a perfect short, medium and long term BUY recommendation!!
CLICK HERE!!
*************************************************
TODAY’S NEWS!!
NexMed Granted Continued Listing on NASDAQ
About NEXM
NexMed, due to its recent acquisition of Bio-Quant, is the largest specialty contract research organization (“CRO”) based in San Diego, CA and is one of the industry’s most experienced CROs for in vitro and in vivo pharmacology services and research models. NexMed is also developing a proprietary product pipeline based on its NexACT(R) drug delivery technology, including a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil treatment for female sexual arousal disorder and an early stage treatment for psoriasis. For further information, go to www.nexmed.com and www.bio-quant.com.
FINANCE & NEWS